National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
Search
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Ovarian Epithelial Cancer Treatment (PDQ®)
Patient VersionHealth Professional VersionEn españolLast Modified: 03/05/2008



Purpose of This PDQ Summary






General Information







Cellular Classification






Stage Information






Stage I and Stage II Ovarian Epithelial Cancer






Stage III and Stage IV Ovarian Epithelial Cancer






Recurrent or Persistent Ovarian Epithelial Cancer






Get More Information From NCI






Changes to This Summary (03/05/2008)






More Information



Page Options
Print This Page  Print This Page
Print This Document  Print Entire Document
View Entire Document  View Entire Document
E-Mail This Document  E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

NIH Calendar of Events

Español
NCI Highlights
New Study of Targeted Therapies for Breast Cancer

The Nation's Investment in Cancer Research FY 2009

President's Cancer Panel Annual Report: 2006-2007

Cancer Trends Progress Report: 2007 Update

Past Highlights
HPV Vaccines for Cervical Cancer
Cellular Classification

The following is a list of ovarian epithelial cancer histologic classifications.

  • Serous cystomas:
    • Serous benign cystadenomas.


    • Serous cystadenomas with proliferating activity of the epithelial cells and nuclear abnormalities but with no infiltrative destructive growth (low potential or borderline malignancy).


    • Serous cystadenocarcinomas.




  • Mucinous cystomas:
    • Mucinous benign cystadenomas.


    • Mucinous cystadenomas with proliferating activity of the epithelial cells and nuclear abnormalities but with no infiltrative destructive growth (low potential or borderline malignancy).


    • Mucinous cystadenocarcinomas.




  • Endometrioid tumors (similar to adenocarcinomas in the endometrium):
    • Endometrioid benign cysts.


    • Endometrioid tumors with proliferating activity of the epithelial cells and nuclear abnormalities but with no infiltrative destructive growth (low malignant potential or borderline malignancy).


    • Endometrioid adenocarcinomas.




  • Clear cell (mesonephroid) tumors:
    • Benign clear cell tumors.


    • Clear cell tumors with proliferating activity of the epithelial cells and nuclear abnormalities but with no infiltrative destructive growth (low malignant potential or borderline malignancy).


    • Clear cell cystadenocarcinomas.




  • Unclassified tumors that cannot be allotted to one of the above groups.


  • No histology.


  • Other malignant tumors (malignant tumors other than those of the common epithelial types are not to be included with the categories listed above).


(Refer to the PDQ summary on Ovarian Low Malignant Potential Tumor Treatment for more information.)

Back to TopBack to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov